Cited in:


This article has been cited by:

  1. 1
    Alessia Dalla Pria, Mark Nelson, Mark Bower, Targeted treatment of HHV-8-associated multicentric Castleman's disease, Expert Opinion on Orphan Drugs, 2013, 1, 3, 189


  2. 2
    Ibrahiem Saeed-Abdul-Rahman, Ali M. Al-Amri, Castleman disease, The Korean Journal of Hematology, 2012, 47, 3, 163


  3. You have free access to this content3
    Claire E. Dearden, Rod Johnson, Ruth Pettengell, Stephen Devereux, Kate Cwynarski, Sean Whittaker, Andrew McMillan, Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma), British Journal of Haematology, 2011, 153, 4
  4. You have free access to this content4
    Laurence De Leval, Christian Gisselbrecht, Philippe Gaulard, Advances in the understanding and management of angioimmunoblastic T-cell lymphoma, British Journal of Haematology, 2010, 148, 5
  5. 5
    José Rodríguez, Eulogio Conde, Antonio Gutiérrez, Reyes Arranz, Marcos Gandarillas, Angel Leon, Jesus Ojanguren, Anna Sureda, Dolores Carrera, Mauricio Bendandi, Jose Moraleda, Jose Maria Ribera, Carmen Albo, Alfonso Morales, Juan Carlos García, Pascual Fernández, Guillermo Cañigral, Juan Bergua, María Dolores Caballero, Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. The GELTAMO experience, European Journal of Haematology, 2007, 78, 4
  6. 6
    Ahmet Dogan, Ayoma D. Attygalle, Chara Kyriakou, Angioimmunoblastic T-cell lymphoma, British Journal of Haematology, 2003, 121, 5
  7. 7
    R. Hast, B. Gustafsson, Improved response to chemotherapy after interferon alpha-2b in angioimmunoblastic lymphadenopathy (AILD), European Journal of Haematology, 1991, 46, 1
  8. 8
    Ingo Meuthen, Karl Lennert, Wolfgang Siegert, LYMPHOGRANULOMATOSIS X: COMPLETE REMISSION BY LOW DOSE INTERFERON-ALPHA, British Journal of Haematology, 1990, 75, 3